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Melatonin (MLT) is a strong free radical scavenger that protects the body from the deleterious effects of 
excess oxidants. Synthesis of MLT analogue compounds with antioxidant potency has recently attracted 
the interest of researchers. In general, the strategy consists of modifying the groups in the different sites 
of the indole ring or replacing the indole ring with an analogue. As part of our ongoing research, the 
antioxidant capacity and cytotoxicity of newly synthesized MLT analogue naphthalene derivatives were 
evaluated. The radical scavenging activity was tested by a 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay. 
Most of the synthesized compounds showed significant antioxidant activity in comparison to MLT. The 
structure-activity relationship was identified. The in vitro cytotoxic effects of the synthesized compounds 
were also investigated in CHO-K1 cells using the MTT assay. 
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INTRODUCTION
Melatonin (MLT) is a neurohormone secreted by 
the pineal gland in the human body (Maharaj et al., 2005). 
Biosynthesis of MLT (N-acetyl-5-methoxytrypamine) 
starts with the amino acid L-tryptophan which is a 
precursor amino acid for synthesizing both serotonin and 
MLT in the pineal gland (Yonei et al., 2010). MLT has 
been recognized as a specific hormone of the pineal gland, 
but it is also secreted in the gastrointestinal tract, skin, 
retina, brain and some other parts of the body (Reiter et al., 
2000; Suzuki et al., 2008). MLT and its derivatives are 
responsible of the regulation of the circadian rhythm. 
In addition to this important function, MLT performs 
numerous tasks in the body such as oncostatic effects, 
immune modulation and antioxidant activities (Danilov, 
Kurganova, 2016). Overproduction of reactive oxygen 
species (ROS) can cause oxidative stress (OS), which may 
lead to vital damage to cell structures such as proteins and 
DNA (Valko et al., 2007; Yamashita et al., 2013). MLT and 
its metabolites have noteworthy antioxidant properties and 
are able to function as endogenous free-radical scavengers 
(Reiter et al., 1999; Shirinzadeh et al., 2016). According to 
recent research, MLT has protective effects in some of OS-
related diseases such as Huntington’s disease, Parkinson’s 
disease, Alzheimer’s disease and ageing (Suzen, 2007; 
Allegra et al., 2003; Suzen et al., 2013; Carocci, Catalano, 
Sinicropi, 2014). 
Long-term studies on the MLT molecule brought 
about only a few commercialized MLT analogues such 
as Circadin, ramelteon, agomelatine and Tasimelteon 
(Lemoine, Zisapel, 2012; Hirai et al., 2005). Substitution 
of the indole ring of MLT with other rings which are 
isosteres for indole was of major interest. One of the 
isostere rings is naphthalene (Landagaray et al., 2016). 
Agomelatine is the first naphthalenic analogue of 
MLT that was confirmed as an antidepressant agent 
for treatment of major depressive disorders by the 
European Medicines Agency (Ettaoussi et al., 2012). 
Many studies have reported the antioxidant properties of 
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agomelatine (Aguiar et al., 2013). As part of our ongoing 
research, naphthalene derivatives analogous to MLT 
were synthesized (De Mello et al., 2016; Azim, Agarwal, 
Vohora, 2017). In general, the strategy in this study 
consisted of replacing the indole ring with the bioisosteric 
naphthalene ring. All twenty-one compounds except 1h 
(Robev, 1981), 1r (Robev, 1968) and 1u (Weil, Ostermeier, 
1921; Ding et al., 2017) were new. Furthermore, the 
compounds 1n, 1p and 1o have CAS registry numbers, 
but there is no information in the literature related to the 
biological activity of these. The synthesized compounds 
were characterized on the basis of 1H and 13C NMR, mass 
spectra and elemental analyses. The biological activity 
of the compounds was investigated in in vitro conditions 
by a well-known 1,1-diphenyl 2-picrylhydrazyl (DPPH) 
radical scavenging activity assay. The in vitro cytotoxic 
effects of the synthesized compounds were investigated 
in CHO-K1 cells using the MTT assay. 
MATERIAL AND METHODS
This study was designed to synthesize, characterize 
and investigate the potential antioxidant and cytotoxic 
effects of new MLT analogue compounds containing the 
naphthalene ring instead of the indole ring. Two major 
modifications may be seen on MLT. The first one was the 
replacement of the indole ring of MLT with naphthalene 
which is bioisosteric with indole. The second modification 
was made on the acetylamino-ethyl side chain by formation 
of imine (Figure 1). Two series of new compounds were 
synthesized (Table I). It is known that there are different 
opinions about the antioxidant efficacy of the methoxy 
group in the MLT molecule (Shirinzadeh et al., 2010; 
Spadoni et al., 2006; Letra-Vilela et al., 2016). To 
identify the antioxidant role of the methoxy group on 
the naphthalene ring, 6-methoxy naphthalene and non-
methoxy naphthalene series were synthesized.
Chemistry – experimental
Uncorrected melting points were determined 
with a Stuart melting point SMP30 apparatus. The 1H 
and 13C NMR spectra were measured with a Varian 400 
MHz spectrometer device (Palo Alto, CA) using TMS 
as an internal standard and DMSO-d6 as solvent. ESI 
mass spectra were determined by a Waters Micromass 
ZQ device. Elemental analyses were performed using a 
CHNS-932 instrument (Leco Corporation, St. Joseph, 
FIGURE 1 - Modifications on MLT molecule to develop new analogues.
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MI). All spectral analyses were performed at the Central 
Laboratory of the Faculty of Pharmacy at Ankara 
University. Chromatography was carried out using Merck 
silica gel 60 (230–400 mesh ASTM). The chemical 
reagents that were used in synthesis were purchased from 
Sigma (Germany) and Aldrich (USA).
Chemistry
The designed compound was synthesized by 
condensation of phenylhydrazine with 6-methoxy-2-
naphthaldehyde or 2-naphthaldehyde. All new imines 
were obtained by using a methodology similar to that 
in a previous study (Kidwai, Negi, Gupta, 1994). The 
synthesized compounds were characterized on the basis 
of 1H and 13C NMR, mass spectra and elemental analyses.
General procedure for the synthesis of 
compounds 1a-u
1 mmol of 6-methoxy-2-naphthaldehyde and 1.3 
mmol of phenyl hydrazine hydrochloride or its derivatives 
were dissolved in absolute ethanol (20 mL) and heated for 
60 min on a hot water bath in the presence of CH3COONa 
(0.4 g). After completion of the reaction, the reaction 
mixture was cooled to room temperature. The precipitate 
was collected, washed with cold EtOH and recrystallized 
from EtOH to achieve 1a–u with 60 to 94% yield.
1-(2-bromophenyl)-2-((6-methoxynaphthalen-2-yl)
methylene)hydrazine (1a)
Yield 94.63%, m.p. 148 °C;1H-NMR: δ 3.93 (s, 3H, 
OCH3); 6.73-8.00 (m, 10H ArH); 7.81 (s, 1H, NH);7.94 (s, 
1H, HC=N); 13C-NMR: δ 55.35 (OCH3), 106.15, 106.84, 
114.58, 119.14, 120.53, 123.59, 127.02, 127.35, 128.59, 
128.72, 129.67, 130.50, 132.26, 135.05, 140.13, 141.57 
(HC=N), 158.24: MSI MS m/z 355 (M+, 90 %), 357 (M+2, 
100 %). Anal. calcd. for C18H15BrN2O: C, 60.86%; H, 
4.26%; N, 7.89%. Found: C, 60.76%; H, 4.78%; N, 7.61%.
1-(3-bromophenyl)-2-((6-methoxynaphthalen-2-yl)
methylene)hydrazine (1b)
Yield 86.77%, m.p. 205 °C; 1H-NMR: δ 3.91 
(s, 3H, OCH3); 6.86-7.99 (m, 10H ArH); 7.98 (s, 1H, 
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HC=N); 10.52 (s, 1H, NH) ; 13C-NMR: δ 55.22 (OCH3), 
106.32, 111.02, 113.98, 118.88, 120.85, 122.45, 123.03, 
126.27, 127.23, 128.38, 129.49, 130.89, 131.03, 134.38, 
138.41,146.91 (C=N), 157.63: MSI MS m/z 355 (M+, 100 
%), 357 (M+2 100, %). Anal. calcd. for C18H15BrN2O: 




Yield 88.13%, m.p. 198 °C; 1H-NMR: δ 3.86 (s, 3H, 
OCH3); 7.03-7.92 (m, 10H ArH); 7.97 (s, 1H, HC=N); 
10.47 (s, 1H, NH) ; 13C-NMR: δ 55.14 (O-C), 106.25, 
109.26, 113.74, 118.79, 122.93, 125.97, 127.10, 128.33, 
129.37, 130.99, 131.63, 134.21, 137.70, 144.57 (C=N), 
157.50 (O-C): MSI MS m/z 355 (M+, 100 %), 357 (M+2, 
95 %). Anal. calcd. for C18H15BrN2O: C, 60.86%; H, 
4.26%; N, 7.89%. Found: C,60.78%; H, 4.37%; N, 8.04%.
1-(2-chlorophenyl)-2-((6-methoxynaphthalen-2-yl)
methylene)hydrazine (1d)
Yield 60%, m.p. 148 °C; 1H-NMR: δ 3.87 (s, 3H, 
OCH3); 6.76-7.94 (m, 10H ArH); 8.39 (s, 1H, HC=N); 
9.90 (s, 1H, NH) ; 13C-NMR: δ 55.23 (OCH3), 106.32, 
114.02, 116.07, 118.89, 119.47, 123.08, 126.48, 127.25, 
128.03, 128.38, 129.32, 129.57, 130.95, 134.49, 140.66, 
141.46 (C=N), 157.69(O-C): MSI MS m/z 311 (M+H, 
100 %), 313(M+2, 34%). Anal. calcd. for C18H15ClN2O: 




Yield 64.5%, m.p. 203 °C; 1H-NMR: δ 3.86 (s, 3H, 
OCH3); 6.73-7.93 (m, 10H ArH); 7.99 (s, 1H, HC=N); 
10.53 (s, 1H, NH) ; 13C-NMR: δ 55.22 (OCH3), 106.33, 
110.66, 111.14, 117.97, 118.88, 123.05, 126.26, 127.23, 
128.39, 129.49, 130.71, 130.92, 133.87, 134.39, 138.36, 
146.81 (C=N), 157.63 (O-C): MSI MS m/z 311 (M+H, 
100 %), 313(M+2, 35 %). Anal. calcd. for C18H15ClN2O: 




Yield 83.87%, m.p. 221 °C; 1H-NMR: δ 3.86 (s, 3H, 
OCH3); 7.07-7.92 (m, 10H ArH); 7.97 (s, 1H, HC=N); 
10.46 (s, 1H, NH) ; 13C-NMR: δ 55.21 (OCH3), 106.32, 
113.34, 118.86, 121.79, 123.01, 126.00, 127.17, 128.42, 
128.88, 129.44, 131.09, 134.28, 137.67, 144.28 (C=N), 
157.57 (O-C): MSI MS m/z 311 (M+H, 100 %), 312 
(M+1, 32 %). Anal. calcd. for C18H15ClN2O: C, 69.56%; H, 
4.86%; N, 9.01%. Found: C,69.61%; H, 5.08%; N, 9.13%.
1-(4-fluorophenyl)-2-((6-methoxynaphthalen-2-yl)
methylene)hydrazine (1g)
Yield 85.03%, m.p. 206 °C; 1H-NMR: δ 3.85 (s, 3H, 
O CH3 ), 7.03-7.92 (m, 10H, Ar- H ), 7.96 (s, 1H, HC=N 
), 10.32 (s, 1H, NH ); 13C-NMR: δ 55.20 (OCH3 ), 106.31, 
112.85, 115.48, 115.70, 118.83, 123.01, 125.72, 127.15, 
128.46, 129.39, 131.31, 134.17, 136.88, 142.08 (C=N), 
154.65, 156.97, 157.49 (O-C); MSI MS m/z 295 (M+H, 
100 %), 296 (M++1, 28 %). Anal. calcd. for C18H15FN2O: 




Yield 82.26%, m.p. 169 °C; 1H-NMR: δ 2.18 (s, 
6H, Ar- CH3 ), 3.86 (s, 3H, OCH3), 6.86-7.92 (m, 9H, 
Ar-H), 8.20 (s, 1H, HC=N), 9.44(s, 1H,NH); 13C-NMR: 
δ 17.37 (Ar- CH3 ), 20.11; (Ar- CH3 ), 55.17 ( OCH3 ), 
106.30, 112.23, 118.74, 120.60, 123.04, 125.49, 127.06, 
127.12, 128.47, 129.36, 130.88, 131.54, 134.11, 137.67, 
141.00 (C=N), 157.41 (O-C); MSI MS m/z 305 (M+H, 
100 %), 306 (M++1, 32 %). Anal. calcd. for C20H20N2O: 




Yield 83.87%, m.p. 230 °C; 1H-NMR: δ 2.11 ( s, 3H 
, Ar- CH3 ), 2.18 ( s, 3H , Ar- CH3 ), 3.85 ( s, 3H , OCH3 ), 
6.80-7.90 ( m, 9H , Ar-H ), 7.92 ( s, 1H , HC=N), 10.14 ( 
s, 1H , NH ); 13C-NMR: 18.55 (Ar- CH3 ), 19.76 (Ar- CH3 
), 55.19 (OCH3 ), 106.31, 109.48, 113.30, 118.78, 123.02, 
125.41, 125.99, 127.12, 128.50, 129.34, 130.03, 131.56, 
134.04, 135.95, 136.62, 143.39 (C=N), 157.39 (O-C); 
MSI MS m/z 305 (M+H, 100 %), 306 (M++1, 65 %). Anal. 
calcd. for C20H20N2O: C, 78.92%; H, 6.62%; N, 9.20%. 
Found: C,78.42%; H, 6.46%; N, 9.18%.
1-((6-methoxynaphthalen-2-yl)methylene)-2-
phenylhydrazine (1j)
Yield 90.68%, m.p. 229 °C; 1H-NMR: δ 3.86 (s, 3H, 
OCH3); 6.72-7.93 (m, 11H ArH); 7.97 (s, 1H, HC=N); 
10.29 (s, 1H, NH) ; 13C-NMR: δ 55.20 (OCH3), 106.31, 
111.94, 118.60, 118.82, 123.03, 125.69, 127.15, 128.46, 
129.10, 129.40, 131.38, 134.16, 136.79, 145.40 (C=N), 
157.47(O-C): MSI MS m/z 277 (M+H, 100 %). Anal. 
calcd. for C18H16N2O: C, 78.24%; H, 5.84%; N, 10.14%. 
Found: C,77.99%; H, 5.84%; N, 10.10 %. 
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1-(2-bromophenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1k)
Yield 83.10%, m.p. 163 °C; 1H-NMR: δ 6.72-8.02 
(m, 11H ArH); 8.46 (s, 1H, HC=N); 9.77 (s, 1H, NH) 
; 13C-NMR: δ 106.10, 114.63, 120.40, 122.54, 126.35, 
126.56, 126.60, 127.70, 128.00, 128.30, 128.60, 132.59, 
133.07, 133.09, 133.19, 140.52, 142.39 (C=N): MSI MS 
m/z 325 (M+, 100 %), 327 (M+2, 100 %). Anal. calcd. 
for C17H13BrN2: C, 62.79%; H, 4.03%; N, 8.61%. Found: 
C,62.61%; H, 4.13%; N, 8.79%.
1-(3-bromophenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1l)
Yield 75.40%, m.p. 175 °C; 1H-NMR: δ 6.88-7.98 
(m, 11H ArH); 8.03 (s, 1H, HC=N); 10.62 (s, 1H, NH) 
; 13C-NMR: δ 111.13, 114.12, 121.10, 122.47, 122.49, 
126.25, 126.35, 126.53, 127.69, 127.91, 128.26, 131.06, 
132.95, 133.10, 133.14, 138.09, 146.78 (C=N): MSI MS 
m/z 325 (M+, 95 %), 327 (M+2, 100 %). Anal. calcd. for 
C17H13BrN2: C, 62.79%; H, 4.03%; N, 8.61%. Found: 
C,62.46%; H, 4.09%; N, 8.75%.
1-(4-bromophenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1m)
Yield 65.86%, m.p. 218 °C; 1H-NMR: δ 7.05-7.97 
(m, 11H ArH); 8.02 (s, 1H, HC=N); 10.58 (s, 1H, NH) 
; 13C-NMR: δ 109.68, 113.97, 122.46, 126.11, 126.17, 
126.53, 127.68, 127.86, 128.21, 131.74, 132.88, 133.13, 
133.30, 137.45, 144.51 (C=N): MSI MS m/z 325 (M+, 
93 %), 327 (M+2, 100 %). Anal. calcd. for C17H13BrN2: 




Yield 85.71%, m.p. 168 °C; 1H-NMR: δ 6.77-8.01 
(m, 11H ArH); 8.43 (s, 1H, HC=N); 10.01 (s, 1H, NH) 
; 13C-NMR: δ 114.13, 116.20, 119.69, 122.51, 126.34, 
126.55, 126.57, 127.68, 127.98, 128.05, 128.30, 129.36, 
133.06, 133.10, 133.20,140.33, 141.35 (C=N) : MSI MS 
m/z 281 (M+H, 100 %), 283 (M++2, 34 %). Anal. calcd. 
for C17H13ClN2: C, 72.73%; H, 4.67%; N, 9.98%. Found: 
C,72.65%; H, 4.76%; N, 10.02%.
1-(3-chlorophenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1o)
Yield 82.14%, m.p.172 °C; 1H-NMR: δ 6.75-7.99 
(m, 11H ArH); 8.03 (s, 1H, HC=N); 10.63 (s, 1H, NH) 
; 13C-NMR: δ 111.24, 111.72, 118.68, 122.98, 126.73, 
126.81, 127.02, 128.17, 128.39, 128.74, 131.24, 133.43, 
133.58, 133.62, 134.35, 138.51, 147.14 (C=N): MSI MS 
m/z 281 (M+H, 100 %), 283 (M++2, 32 %). Anal. calcd. 
for C17H13ClN2: C, 72.73%; H, 4.67%; N, 9.98%. Found: 
C,72.03%; H, 4.73%; N, 9.88%.
1-(4-chlorophenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1p)
Yield 85%, m.p. 223 °C; 1H-NMR: δ 7.07-7.97 
(m, 11H ArH); 8.01 (s, 1H, HC=N); 10.57 (s, 1H, NH) 
; 13C-NMR: δ 113.46, 122.04, 122.47, 126.07, 126.16, 
126.53, 127.69, 128.86, 128.21, 128.92, 132.88, 133.14, 
133.33, 137.35, 144.15 (C=N): MSI MS m/z 281 (M+H, 
100 %), 283 (M++2, 35 %). Anal. calcd. for C17H13ClN2: 




Yield 77%, m.p. 200 °C; 1H-NMR: δ 6.50-7.99 
(m, 11H, Ar-H), 8.03 (s, 1H, HC=N), 10.65 (s, 1H, NH); 
13C-NMR: δ 98.54, 104.78, 104.99, 108.19, 122.54, 
126.24, 459.53, 127.69, 127.90, 128.24, 130.70, 132.94, 
133.16, 137.76, 147.23 (C=N), 162.19, 164.58; MSI MS 
m/z 265 (M+H, 100 %), 266 (M++1, 24 %). Anal. calcd. for 
C17H13FN2: C, 77.25%; H, 4.96%; N, 10.60%. Found: 
C,76.91%; H, 5.04%; N, 10.62%.
1-(4-fluorophenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1r)
Yield 90.90%, m.p. 232 °C; 1H-NMR: δ 7.04-7.98 
(m, 11H, Ar-H), 8.00 (s, 1H, HC=N), 10.43 (s, 1H, NH); 
13C-NMR: δ 112.99,115.75, 122.47, 125.77, 126.50, 
127.67, 127.81, 128.17, 132.79, 133.17, 136.53, 141.91 
(C=N), 154.77, 157.09; MSI MS m/z 265 (M+H, 100 %), 
266 (M++1, 30 %). Anal. calcd. for C17H13FN2: C, 77.25%; 




Yield 85.71%, m.p. 178 °C; 1H-NMR: δ 2.18 ( s, 3H, 
Ar- CH3 ), 2.20 ( s, 3H, Ar- CH3 ), 6.87-7.98 ( m, 10H, ArH 
), 8.24 ( s, 1H, HC=N ), 9.57 ( s, 1H, NH ); 13C-NMR: δ 
17.43 (Ar- CH3 ), 20.17 (Ar- CH3 ), 112.37, 120.76, 122.52, 
125.58, 125.98, 126.47, 127.14, 127.40, 127.66, 127.82, 
128.19, 130.96, 132.77, 133.23, 133.81, 137.33, 140.88 
(C=N); MSI MS m/z 275 (M+H, 100 %). Anal. calcd. 
for C19H18N2: C, 83.18%; H, 6.61%; N, 10.21%. Found: 
C,82.58%; H, 6.64%; N, 10.14%.
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1-(3,4-dimethylphenyl)-2-(naphthalen-2-ylmethylene)
hydrazine (1t).
Yield 78.57%, m.p. 218 °C; 1H-NMR: δ 2.12 ( s, 3H, 
Ar- CH3 ), 2.18 ( s, 3H, Ar- CH3 ), 6.82-7.98 ( m, 10H, Ar- 
H ), 7.85 ( s, 1H, HC=N ), 10.25 ( s, 1H, NH ); 13C-NMR: 
δ 18.55 (Ar- CH3 ), 19.76 (Ar- CH3 ), 109.57, 113.38, 
122.48, 125.42, 125.88, 126.22, 126.43, 127.65, 127.75, 
128.11, 130.04, 132.66, 133.22, 133.78, 135.58, 136.65, 
143.22 (C=N); MSI MS m/z 275 (M+H, 100 %). Anal. 
calcd. for C19H18N2: C, 83.18%; H, 6.61%; N, 10.21%. 
Found: C,82.90%; H, 6.63%; N, 10.18%.
1-(naphthalen-2-ylmethylene)-2-phenylhydrazine (1u)
Yield 79.67%, m.p.223 °C; 1H-NMR: δ 6.73-7.98 
(m, 12H ArH); 8.01 (s, 1H, HC=N); 10.44 (s, 1H, NH) 
; 13C-NMR: δ 112.04, 118.82, 122.48, 125.74, 126.02, 
126.48, 127.67, 127.81, 128.17, 129.12, 132.77, 133.18, 
133.61, 136.44, 145.21 (C=N): MSI MS m/z 247 (M+H, 
100 %). Anal. calcd. for C17H14N2: C, 82.90%; H, 5.733%; 
N, 11.37%. Found: C,82.30%; H, 5.79%; N, 11.29%. 
All the experimental and characterization data of 1u 
are in agreement with the literature. (Weil, Ostermeier, 
1921)
EXPERIMENTAL – BIOLOGICAL ACTIVITY
Cell culture and chemicals
The CHO-K1 cell line (ATCC) was maintained with 
Dulbecco’s Modified Eagle Serum/F12 Ham (DMEM: 
F12) which was supplemented with 10% fetal bovine 
serum (FBS) and 1mM sodium pyruvate at 37 °C and in a 
humidified atmosphere containing 5% CO2. Cell culture 
media and assay chemicals were obtained from Sigma-
Aldrich (St. Louis, MO) except for FBS (Gibco, Grand 
Island, NY) and sodium pyruvate (Santa Cruz Biotech. 
Inc., TX).
Free radical scavenging activity evaluation with 
DPPH assay
2,2-diphenyl-1-picrylhydrazyl (DPPH) is a stable 
free radical with a maximum absorbance of 520 nm. 
DPPH is reduced with the absence of an antioxidant 
molecule and loses its reactivity. Thereby, the solution with 
a dark blue color becomes colorless (Blois, 1958). The 
DPPH assay was performed just as our previous protocol 
(Carocci et al., 2014). The novel compounds were added 
into 150 µL of DPPH methanol: water (4:1) solution 
with final concentrations of 10µM and 100µM in 96-well 
plates. DPPH reduction was monitored in a microplate 
reader at a wavelength of 517 nm for 60 minutes. The 
radical scavenging activities of the molecules (RSA) were 
calculated as:
RSA % = ((A0-A1) / A0x100)
A0: absorbance value of solvent control - DPPH solution 
containing 10% DMSO - A1: molecular absorbance value 
- 180 μL DPPH solution containing 20 μL molecule of 
DMSO solution.
Cytotoxicity evaluation with MTT assay
MTT (3- (4 ,5 -d imethy l th iazo l -2 -y l ) -2 ,5 -
diphenyltetrazolium bromide) is a water-soluble 
tetrazolium salt. MTT is reduced to purple formazan 
crystals by the mitochondrial succinate dehydrogenase 
enzyme. Formazan crystals are dissolved in the 
appropriate solvent, and the optical density is measured 
in a spectrophotometer (Niles, Moravec, Riss, 2008).
CHO-K1 cells were plated at a concentration 
of 5000 cells / well in 96-well plates. The cells were 
incubated for 24 hours in a humidified environment 
containing 5% CO2 at 37 °C. The final concentrations 
of the test substances were added to the cell medium 
at 10 μM, and incubation was carried out with the test 
substances for 24 hours. Control (medium), vehicle 
control (0.1% DMSO) and positive control (171 μM 
Triton X-100) groups were used in all experiments. 
After exposure to the test substances, the media were 
removed, and the wells were washed with phosphate-
buffered saline (PBS). The wells which contained the 
cells were incubated for 4 hours in a MTT solution 
with a final concentration of 1 mg/mL in the medium 
(Mossman, 1983). After incubation, the MTT solution 
was removed from the wells, and the formazan crystals 
were dissolved in 150 μL of DMSO. Absorbance values 
were recorded in a Thermo / Varioskan Flash microplate 
reader at a wavelength of 550 nm. The effect of the novel 
compounds on cell viability was calculated as % viability 
in comparison to the vehicle control (the viability of the 
vehicle control was accepted as 100%).
Statistical analyses
The statistical analyses of the DPPH and MTT 
experiments were carried out by using the parametric 
method of “student’s t-test”.
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RESULTS
Antioxidant activities of novel compounds
The radical scavenging activities of the novel 
compounds were investigated by the DPPH assay at 
final concentrations of 10 μM and 100 μM (Figure 1). 
According to these results, all molecules exhibited 
statistically significant radical scavenging activity in 
comparison to the vehicle control.
Effects on cell viability of novel compounds
The effects of the molecules on cell viability were 
demonstrated by the MTT assay. The antiproliferative 
effects of the molecules were investigated at the final 
concentration of 10 μM in 0.1% DMSO (Figure 3).
DISCUSSION AND CONCLUSION
Biological processes such as aging are thought to play 
a role in oxidative stress in the pathology of many diseases 
such as diabetes, atherosclerosis, rheumatoid arthritis and 
cancer. Therefore, external antioxidant supplementation 
and/or strengthening of the body’s antioxidant defense 
system are proposed as treatment approaches for these 
diseases. One of the mechanisms of action of antioxidant 
molecules is cleaning/scavenging of reactive oxygen 
derivatives. In this study, novel compounds were 
synthesized by bioisosteric modification of the indole ring 
of MLT, and the possible antioxidant potentials of these 
compounds were studied by investigating their radical 
scavenging activities. The radical scavenging activities 
of the 1-(halogenated phenyl)-2-((6-methoxynaphthalen-
2-yl)methylene)hydrazine derivatives (1a-j) were higher 
than those of the 1-(halogenated phenyl)-2-naphthalen-2-
yl)methylene)hydrazine (1k-u) derivatives. It is believed 
that the 6-methoxy substitution process in these halogen-
bearing derivatives may have increased their activity. 
In the halogen-free derivatives, methoxy substitution 
(1i, 1j) was not found to cause an increase in activity in 
comparison to the non-methoxy-substituted derivatives 
(1t, 1u). The presence of halogen in the o-position reduced 
the radical scavenging activity (1a, 1d, 1l & 1o), but m- 
and p-halogen substitution increased the activity of the 
phenyl substitution in the hydrazine group.
One of the factors causing the greatest time, cost and 
labor loss in drug discovery and development studies is 
FIGURE 2 - Radical scavenging activities of the novel compounds according to the DPPH assay. Bars represent “% RSA Mean 
± standard deviation”. Melatonin (MLT) and butylhydroxytoluene (BHT) were used as reference compounds. The results were 
obtained by studying three different groups for each molecule. Statistically significant values (p <0,05) were expressed with “*”.
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that a candidate compound that is found at the late stages 
of studies might be thrown away as all work is finally 
done, so it is a possibility that the toxic effects of such 
a candidate compound are not studied. For this reason, 
the pharmaceutical industry and regulatory agencies 
recommend in vitro rapid screening tests to be conducted 
at the early stages of drug discovery and development 
studies, and accordingly, investigation of the cytotoxicity 
of such substances will prevent these losses. In the light 
of these information and proposals, the possible cytotoxic 
effects of the novel compounds were investigated in a 
healthy cell line by the MTT assay in our study. The MTT 
assay detects the viable cells with active metabolism which 
convert MTT into a purple colored formazan product. 
Thus, color formation serves as a convenient marker of 
only the viable cells. The findings indicated that there 
was no significant structure-activity relationship in the 
potentially cytotoxic effects of the substances, but the 
6-methoxy naphthalene compounds seemed to be more 
cytotoxic than the non-methoxy naphthalene compounds. 
Moreover, the ortho halogenation on the phenyl ring was 
found to decrease the cytotoxic potential of the compounds 
in general. Some substances that are found to have radical 
scavenging effects appear to have cytotoxic potency. For 
this reason, it is recommended to evaluate and confirm 
the radical scavenging/antioxidant effects in a cell-based 
in vitro model and determine the cytotoxicity potential of 
the substances at their effective concentrations. It is also 
possible to investigate the mechanisms of their cytotoxic 
effects by using a battery of cytotoxicity assays based on 
various mechanisms instead of a sole assay, MTT. 
Z,E-isomerism evaluation of the synthesized 
compounds
Molecules that have the hydrazono group with 
other functional groups have some special physical and 
chemical properties. In most cases, these compounds can 
exist as either anti-E or syn-Z isomers. The 1Н, 13С and 15N 
NMR spectroscopic techniques and an X-ray diffraction 
of single crystals are much more informative tools for 
the study of the fine structure of hydrazono-compounds 
including information on Z,E-isomerism and hydrogen 
bonding.
Studies in the literature with compounds that are 
structurally similar to naphthalene-hydrazone derivatives 
showed that these molecules exist as anti-E isomers 
(Figure 4). The structure of 2-thiophenecarbaldehyde 
2-quinolylhydrazone (A) was investigated by Mague et al. 
(1997) using X-ray Crystallographic methods, and the 
molecule was found in the anti-E isomer form. Based 
on our previous study (Yilmaz, Coban, Suzen, 2011), 
we observed that the twenty-one synthesized indole 
hydrazide/hydrazone (B) derivatives (except for one 
derivative) existed as anti-E isomers. Our research 
on quinolone hydrazine derivatives showed similar 
results (Puskullu et al., 2015). A series of quinoline-2-
carboxaldehydes hydrazones was synthesized (C) and 
FIGURE 3 - Effects of novel compounds on cell viability in CHO cells. Bars represent the “% cell viability mean ± standart deviation” 
values from 3 separate experiments for each molecule. % Viability evaluation was calculated according to solvent control (DMSO 
0.1%). Triton X-100 was used as a positive control. Statistical significance was expressed as * p <0,05; ** p <0.01; *** p <0.005.
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characterized. None of the compounds showed syn-Z 
isomers according to the findings of the 1Н, 13С and 15N 
NMR spectroscopic analyses. In this study, we observed 
similar results with naphthalene derivatives (D). No 
signals were detected to represent isomerism by the 1Н, 13С 
NMR analyses. These literature data and reports (Soltani 
Rad, Khalafi-Nezhad, Behrouz, 2010), prove that all of the 
synthesized compounds are anti-E isomer.
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